Gilead (GILD) volatility elevated into less than expected Q1 results

Go back to Gilead (GILD) volatility elevated into less than expected Q1 results

Gilead Sciences (GILD) PT Lowered to $90 at RBC Capital

May 2, 2018 8:26 AM EDT

RBC Capital lowered its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $94.00) while maintaining an Outperform rating following a disappointing quarter.

... More

Gilead Sciences (GILD) PT Lowered to $79 at Baird

May 2, 2018 7:51 AM EDT

Baird lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $87.00) while maintaining an Outperform rating on weaker than expected 1Q.

Analyst Brian Skorney commented, "While investors had projected 2018 as a trough earnings year for the company, worse than expected sales... More

Gilead Sciences (GILD) PT Lowered to $81 at Morgan Stanley

May 2, 2018 7:45 AM EDT

Morgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $85.00) while maintaining a Equalweight rating following the company's 1Q earnings report.

1Q18 EPS missed by $0.17. The miss was driven by lower than expected total revenues ($5.1B vs. $5.4B... More